← SynDRA
NINGETINIB
SynDRA canonical compound SYN0038681 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | AXL | KDR | MET |
|---|
| Mechanism of action | protein tyrosine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- MERTK INHIBITOR
- Proto-oncogene tyrosine-protein kinase MER inhibitor
- FLT3 INHIBITOR
- Tyrosine-protein kinase receptor FLT3 inhibitor
- AXL INHIBITOR
- Tyrosine-protein kinase receptor UFO inhibitor
Cross-references
Synonyms
- CT-053 FREE BASE
- CT-053-PTSA FREE BASE
- CT053PTSA FREE BASE
- CT-053 free base
- CT053PTSA free base
- CT-053-ptsa free base
- CT053PTSA
- PW3Q92Z6A4
- NINGETINIB [WHO-DD]
- UNII-PW3Q92Z6A4
- Example 1 [US9133162]
- Example 1 (US9133162)
- RefChem:165958
- Ningetinib Tosylate
- orb1296265
- SCHEMBL12003786
- SCHEMBL29366570
- SCHEMBL29392305
- US9133162, Example 1
- GTPL11624
- VQYYQSZNRVQLIS-UHFFFAOYSA-N
- BDBM180270
- EX-A1889
- NSC781652
- s6870
- AKOS037648725
- HY-107145A
- NSC-781652
- SB16886
- BN168497
- BS-15365
- DA-66105
- CS-0027542
- D80710
- R7I5725FES
- SCHEMBL29465848
- NAUYISNCVNUUDK-UHFFFAOYSA-N
- DA-76188
- HY-107145
Look up NINGETINIB in the interactive SynDRA portal →